Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and inflammation and immunology (I&I), will present a ...

InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference ...

Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanomaPoster ...

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting ...

Tubulis today announced that its late-breaking abstract covering first clinical data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for oral presentation at the upcom ...

Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in ...

Company will feature new data on genomic diagnosis in epilepsy, advocate for expanded testing access, and host a symposium on the evolving role of sequencing in patient care ...

Barcelona, Spain and Düsseldorf, Germany – 22 September, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system ...

The present version of the NCCN guidelines on desmoid tumors similarly align with the Sporadic Desmoid Tumor Working Group consensus statement advising to consider active surveillance up front, and if ...

President Donald Trump, alongside Department of Health and Human Services (HHS) Sec. Robert F. Kennedy Jr. and other medical ...